Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones anticipated for each rare neuromuscular program in 2025, including preparing for Avidity's first BLA submission Commercial preparations well underway in anticipation of three potential successive product launches for DMD, DM1 and FSHD starting in 2026Phase 1/2 EXPLORE44® top-line del-zota data to be presented at the 2025 ...

Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025   On track to complete enrollment in del-desiran HARBORTM Phase 3 and potential registrational del-brax biomarker cohort as well as initiate global pivotal trial for del-brax by mid-2025    Eric Mosbrooker expands role to Chief Commercial Officer; Charles Calderaro III, Chief Technical Officer, and Kat Lange, Chief Business Officer, join as company prepares for global commercialization ...

Avidity Biosciences, Inc. (NASDAQ: RNA ) is rapidly growing into a potential leader in RNA-based genetic therapies, leveraging its Antibody Oligonucleotide Conjugates [AOCs] technology. Since my previous May 2024 article, the stock has appreciated by about 20.3%. This move likely reflects toMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, A ...

Shares of Avidity Biosciences (RNA) rose more than 12% on Wednesday after the company announced that it is expanding its current RNA-based pipeline of rare muscle disorders to explore a new therapeutic area — precision cardiology.Avidity Enters the Cardio Space With Two New DrugsThe company has decided to advance two new wholly-owned pipeline drugs, AOC 1086 and AOC 1072, targeting two rare genetic cardiomyopathies, PLN cardiomyopathy and PRKAG2 syndrome, respectively.There is currently no FDA-approved ther ...

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 17.72%. A quarter ago, it was expected that this company would post a loss of $0.76 per share when it actually produced a loss of $0.65, delivering a surprise of 14.47%.Over the last four quarters, the company has ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value RNA The Nasdaq Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________________________________ FORM 10-Q _____________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 or o TRANSITION REPORT ...

Exhibit 99.1 Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track TM Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a potential accelerated approval path for del-brax TM TM Reported positive del-zota data from Phase 1/2 EXPLORE44 trial for DMD44 Avidity to provide a first look at precision cardiology candidates and a glimpse at next-generation technology innovati ...

Enrollment in global Phase 3 HARBOR™ study for del-desiran in DM1 is on trackAvidity initiated biomarker cohort for del-brax FORTITUDE™ study for FSHD; pursuing a potential accelerated approval path for del-braxReported positive del-zota data from Phase 1/2 EXPLORE44™ trial for DMD44Avidity to provide a first look at precision cardiology candidates and a glimpse at next-generation technology innovations via webcast event November 12, 2024SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nas ...

Avidity Biosciences, Inc. (RNA) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they ...

Avidity to present poster on precision cardiology candidate at American Heart Association (AHA) Scientific Sessions 2024 taking place November 16-18, 2024 Volume 11 of investor and analyst event series will be available via webcast November 12, 2024, at 8:00 a.m. ETSAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the com ...